Incyte Reports 2016 First-Quarter Financial Results And Updates Shareholders On Key Clinical Programs
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) today reported 2016 first-quarter financial results, including strong revenue growth driven by increased Jakafi® (ruxolitinib) sales in the U.S. as well as continued growth in ex-U.S. Jakavi® (ruxolitinib) royalties from Novartis.